Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAD106 Extension Study in Alzheimer's Disease
NCT01023685Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- Feb 2012
- Modality
- Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of amilomotide in Alzheimer's disease (AD), sponsored by Novartis. Started Dec 2009; status: completed.
02
Drugs
amilomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01023685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01023685.